Loading clinical trials...
Loading clinical trials...
RESILIENT is a phase II, multi-center, prospective, pragmatic randomized clinical trial with blinded assessment of the primary endpoint. This study aims to evaluate whether mHealth-CR improves functio...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
NYU Langone Health
Collaborators
NCT05365282 · Ischemic Heart Disease, Nerve Injury, and more
NCT06863155 · Coronary Artery Disease, Ischemic Heart Disease
NCT06631157 · Coronary Artery Disease, Ischemic Heart Disease
NCT05682118 · Ischemic Heart Disease
NCT05788432 · Coronary Artery Disease, Ischemic Heart Disease
UMass Chan Medical School
Worcester, Massachusetts
NYU Langone Health
New York, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions